ValuEngine lowered shares of GRIFOLS S A/S (NASDAQ:GRFS) from a hold rating to a sell rating in a report published on Monday, ValuEngine reports.

A number of other research analysts have also commented on GRFS. Banco Sabadell upgraded GRIFOLS S A/S from a sell rating to a buy rating in a research report on Monday, December 9th. Zacks Investment Research upgraded GRIFOLS S A/S from a sell rating to a hold rating in a research report on Tuesday, January 7th. William Blair restated an outperform rating on shares of GRIFOLS S A/S in a research report on Thursday, December 12th. BidaskClub lowered GRIFOLS S A/S from a buy rating to a hold rating in a research note on Thursday, January 16th. Finally, Berenberg Bank upgraded GRIFOLS S A/S to a buy rating in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. GRIFOLS S A/S presently has a consensus rating of Buy and an average target price of $24.25.

GRFS stock traded up $0.30 during trading on Monday, hitting $24.63. The company had a trading volume of 138,138 shares, compared to its average volume of 952,502. The firm has a 50-day moving average price of $23.54 and a 200-day moving average price of $22.06. GRIFOLS S A/S has a 12 month low of $17.57 and a 12 month high of $24.82. The company has a quick ratio of 0.96, a current ratio of 2.62 and a debt-to-equity ratio of 1.30. The stock has a market cap of $16.78 billion, a price-to-earnings ratio of 27.38, a PEG ratio of 1.25 and a beta of 1.08.

Several large investors have recently modified their holdings of the company. UBS Asset Management Americas Inc. raised its stake in shares of GRIFOLS S A/S by 21.4% during the fourth quarter. UBS Asset Management Americas Inc. now owns 3,017,131 shares of the biotechnology company’s stock worth $70,269,000 after buying an additional 531,849 shares during the last quarter. Marshall Wace LLP lifted its holdings in GRIFOLS S A/S by 46.5% in the fourth quarter. Marshall Wace LLP now owns 1,203,619 shares of the biotechnology company’s stock valued at $28,033,000 after buying an additional 381,935 shares during the period. CSS LLC IL acquired a new position in GRIFOLS S A/S in the fourth quarter valued at approximately $229,000. Marshall Wace North America L.P. boosted its stake in GRIFOLS S A/S by 105.2% in the fourth quarter. Marshall Wace North America L.P. now owns 632,480 shares of the biotechnology company’s stock valued at $14,729,000 after acquiring an additional 324,202 shares during the last quarter. Finally, Fred Alger Management LLC boosted its stake in GRIFOLS S A/S by 1.8% in the fourth quarter. Fred Alger Management LLC now owns 167,238 shares of the biotechnology company’s stock valued at $3,895,000 after acquiring an additional 3,000 shares during the last quarter. Institutional investors own 18.22% of the company’s stock.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

See Also: Initial Coin Offerings entail a high degree of risk

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.